Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer

Table 1 Correlation between kallistatin expression and clinicopathologic parameters

Parameters		n	Kallistatin expression		P value
Parameters		n	Low (n = 144)	High (n = 168)	P value
Age(years)	< 55	149	58	91	0.0170*
Age(years)	≥55	163	86	77	0.0170*
FIGO stage	I + II	60	21	39	0.0614
FIGO stage	III + IV	250	122	128	0.0614
CA125 (U/ml)	< 600	122	57	65	0.6745
CA125 (U/ml)	≥600	174	77	97	0.6745
Ascites (ml)	< 1000	165	67	98	0.0432*
Ascites (ml)	≥1000	146	76	70	0.0432*
Platinum	Resistant	91	30	15	0.0127*
Platinum	Sensitive	45	40	51	0.0127*
Omentum metastasis	Positive	103	101	108	0.2081
Omentum metastasis	Negative	209	42	61	0.2081
Lymph node metastasis	Positive	72	29	27	0.2546
Lymph node metastasis	Negative	56	30	42	0.2546
Recurrence	No	81	29	52	0.0156*
Recurrence	Yes	181	94	87	0.0156*

ISSN: 1757-2215